Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: Association with IL-10 inhibition and increase in TNF-α levels

Journal of Immunology

Volumn 159, Issue 6, 1997, Pages 2658-2667

  Kalechman, Yona ^a   Gafter, Uzi ^b,c   Da, Ji Ping ^a   Albeck, Michael ^a   Alarcon Segovia, Donate ^d   Sredni, Benjamin ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXOETHYLENE O,O' )TELLURATE; AMMONIUM TRICHLORO(DIOXOETHYLENE-O,O'-)TELLURATE; ETHYLENE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MOUSE; MOUSE MUTANT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; CELLS, CULTURED; ETHYLENES; FEMALE; HUMANS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, SCID; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031571886     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Klinman, D. M., and A. D. Steinberg. 1987. Systemic autoimmune disease arises from polyclonal B cell activation. J. Exp. Med. 165:1755.
2. Handwerger, B. S. 1990. Lymphocyte biology in lupus. Curr. Opin. Rheumatol. 2:749.
3. Linker-Israeli, M., R. Deans, D. Wallace, J. Prehn, T. Ozeri-Chen, and J. Klinenberg. 1991. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J. Immunol. 147:117.
4. Llorente, L., Y. Richaud-Patin, J. Wijdenes, J. Alcocer-Varela, M. Maillot, I. Durand-Gasselin, B. Fourrier, P. Galanand, and D. Emilie. 1993. Spontaneous production of IL-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur. Cytokine Netw. 4:421.
5. Alcocer-Varela, J., and D. Alarcon-Segovia. 1982. Decreased production of and response to IL-2 by cultured lymphocytes from patients with SLE. J. Clin. Invest. 69:1388.
6. Hagiwara, E., M. F. Gourley, S. Lee, and D. M. Klinman. 1996. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin 10: Interferon γ secreting cells in the peripheral blood. Arthritis Rheum. 39:379.
7. Tan, P. L., M. Blumenstein, S. Yeoman, and J. D. Watson. 1989. B cell lymphokines in human systemic lupus erythematosus. Ann. Rheum. Dis. 44:941.
8. Flescher, E., D. Fossum, A. Ballester, A. Maizel, S. Sharma, and N. Talal. 1990. Characterization of B cell growth in SLE: effects of recombinant 12-kDa B cell growth factor, interleukin 4 and transforming growth factor-β. Eur. J. Immunol. 20:2425.
9. Theofilopoulos, A. N., and F. J. Dixon. 1985. Murine models of systemic lupus erythematosus. Adv. Immunol. 37:269.
10. Jacob, C. O., and H. O. McDevitt. 1988. Tumor necrosis factor α in murine autoimmune lupus nephritis. Nature 331:356.
11. Gordon, C., G. E. Ranges, J. S. Greenspan, and D. Wofsy. 1989. Chronic therapy with recombinant tumor necrosis factor a in autoimmune NZB/NZWF1 mice. Clin. Immunol. Immunopathol. 52:421.
12. Llorente, L., W. Zou, Y. Levy, Y. Richaud-Patin, Y. Wijdenes, J. Alcocer-Varela, B. Morel-Fourrier, J. C. Brouet, D. Alarcon-Segovia, P. Galanaud, and D. Emilie. 1995. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 181:839.
13. Ishida, H., T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard. 1994. Continuous administration of interleukin 10 antibodies delays onset of autoimmunity in NZB/WF1 mice. J. Exp. Med 179:305.
14. Sredni, B., R. R. Caspi, A. Klein, Y. Kalechman, Y. Danziger, M. Ben Ya'akov, T. Tamari, F. Shalit, and M. Albeck. 1987. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 330:173.
15. Sredni, B., Y. Kalechman, F. Shalit, and M. Albeck. 1990. Synergism between AS101 and PMA in lymphokine production. Immunology 69:110.
16. Sredni, B., Y. Kalechman, M. Albeck, O. Gross, D. Aurbach, P. Sharon, S. N. Sehgal, M. J. Gurwith, and H. Michlin. 1990. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin. Immunology 70:473.
17. Sredni, B., T. Tichler, A. Shani, R. Catane, B. Kaufman, G. Strassmann, M. Albeck, and Y. Kalechman. 1996. Predominance of TH1 response in tumor bearing mice and cancer patients treated with AS101. J. Natl. Cancer Inst. 88:1276.
18. Kalechman, Y., M. Albeck, M. Oron, D. Sobelman, M. Gurwith, S. N. Seghal, and B. Sredni. 1990. Radioprotective effects of the immunomodulator AS101. J. Immunol. 145:1512.
19. Kalechman, Y., and B. Sredni. 1996. Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules. J. Immunol. 157:589.
20. Shani, A., T. Tichler, R. Catane, M. Gurwith, L. A. Rozenszajn, A. Gezin, E. Levi, M. Schlesinger, Y. Kalechman, H. Michlin, F. Shalit, E. Engelsman, H. Farbstein, M. Farbstein, M. Albeck, and B. Sredni. 1990. Immunologic effects of AS101 in the treatment of cancer patients. Nat. Immun. Cell Growth Regul. 9:182.